Perimeter Medical Imaging AI announced on March 3, 2026 that its device, known as Claire, received FDA premarket approval, making it the first AI-enabled imaging system cleared to assess surgical margins during breast cancer surgery in real time. The Toronto- and Dallas-based company plans a nationwide launch in the weeks following the approval, aiming the device at a persistent, costly problem in breast-conserving surgery: leaving cancerous tissue behind.
The Problem Claire Is Built to Solve
Roughly 300,000 breast-conserving surgeries are performed in the United States each year, and by the company’s own figures, about 20% of them currently require a second operation because pathology results, which typically take days to come back, reveal that some cancerous tissue was left at the margin of the excised tissue. Patients are sent home believing surgery removed the cancer, only to be called back weeks later for a repeat procedure once the full pathology report is complete.
How the Technology Works
Claire uses optical coherence tomography, an imaging technique that the company says delivers roughly ten times the resolution of standard X-ray or ultrasound imaging used in the operating room today. Rather than waiting for a pathologist to section and stain excised tissue after the fact, the AI software analyzes the OCT images during the operation itself and flags areas along the tissue margin that appear to still contain cancer, giving the surgeon a chance to remove additional tissue immediately rather than scheduling a second surgery.
The Clinical Evidence
In the pivotal trial data underlying its FDA approval, the device demonstrated 88.1% margin accuracy and was associated with a statistically significant reduction in residual cancer left behind after surgery compared with standard visual and manual inspection alone. The underlying AI model was trained on more than 2 million proprietary OCT images collected specifically for this purpose, according to the company.
What the Company and Investors Are Saying
Perimeter CEO Adrian Mendes framed the approval as a milestone for patients rather than just for the company, saying, ‘Claire’s FDA approval marks a major milestone in breast cancer care, as we advance our goal of reducing repeat surgeries so that no patient has to be told we didn’t get it all.’ Investor Chamath Palihapitiya, whose backing has drawn additional attention to the small-cap medtech company, called it ‘exactly the kind of AI-driven innovation that can improve the standard of care by delivering measurable, real-world medical impacts.’
Open Questions Before Widespread Adoption
An 88.1% margin accuracy rate, while a meaningful improvement over unaided visual inspection, still leaves a real margin of error, and surgeons will need to calibrate how much they trust an intraoperative AI read versus waiting for definitive pathology in ambiguous cases. Because Claire changes surgical decision-making in the moment rather than after the fact, hospitals adopting it will need new operating room workflows, staff training on interpreting the AI output, and capital investment in the OCT hardware itself, all of which typically slow real-world uptake of even well-validated surgical technology. Broader adoption will also depend on how insurers reimburse the added imaging step and whether the reduction in repeat surgeries translates into net cost savings for hospital systems, not just clinical benefit for patients.
What’s Next
With premarket approval now in hand, Perimeter is moving to a nationwide commercial rollout and will be watched closely for real-world data on repeat-surgery rates once the device is deployed outside the controlled conditions of its pivotal trial. Given the enormous volume of eligible surgeries every year in the U.S. alone, even modest reductions in the reoperation rate could translate into tens of thousands of avoided procedures annually if hospitals adopt the technology at scale.
